TY - JOUR
T1 - An evaluation of vilobelimab (anti-C5a) as a cost-effective option to treat severely ill mechanically ventilated patients with COVID-19
AU - Malone, Daniel C.
AU - Biskupiak, Joseph
AU - Brixner, Diana
AU - Oderda, Gary
AU - Seheult, Roger
N1 - Publisher Copyright:
© American Society of Health-System Pharmacists 2024.
PY - 2025/5/1
Y1 - 2025/5/1
KW - COVID-19
KW - QALY
KW - cost-effectiveness analysis
KW - quality adjusted life years
KW - treatment effectiveness
KW - vilobelimab
KW - Quality-Adjusted Life Years
KW - Severity of Illness Index
KW - Antibodies, Neutralizing
KW - Secondary Data Analysis
KW - COVID-19 Drug Treatment
KW - Markov Chains
KW - Double-Blind Method
KW - Humans
KW - Clinical Trials as Topic
KW - COVID-19/mortality
KW - Intensive Care Units/economics
KW - Multicenter Studies as Topic
KW - Cost-Benefit Analysis
KW - Antibodies, Monoclonal, Humanized/economics
KW - Respiration, Artificial/economics
UR - https://www.scopus.com/pages/publications/105004302052
UR - https://www.scopus.com/pages/publications/105004302052#tab=citedBy
UR - https://www.mendeley.com/catalogue/55c5b362-9469-33cc-9abc-e89fdfd25595/
U2 - 10.1093/ajhp/zxae318
DO - 10.1093/ajhp/zxae318
M3 - Article
C2 - 39475087
AN - SCOPUS:105004302052
SN - 1079-2082
VL - 82
SP - e438-e446
JO - American Journal of Health-System Pharmacy
JF - American Journal of Health-System Pharmacy
IS - 9
ER -